Welcome to our dedicated page for Cosmos Health SEC filings (Ticker: COSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cosmos Health Inc. filings document the public-company record of a Nevada healthcare issuer with common stock listed on the Nasdaq Capital Market under COSM. Recent Form 8-K reports cover operating results, Regulation FD disclosures, Nasdaq minimum-bid-price compliance matters, board appointments, annual-meeting voting results and capital-structure proposals involving common stock and blank-check preferred stock.
The filing record also includes a Form 12b-25 notice for a delayed annual report and disclosures tied to business performance across contract manufacturing, wholesale distribution, proprietary nutraceutical brands and research and development. These documents address governance, listing status, share authorization, financial reporting timing and the company's operating subsidiaries and product portfolio.
Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 1,582,313 shares of Cosmos Health Inc. common stock, representing 4.99% of the class. Armistice Capital states it is the investment manager of the direct holder, Armistice Capital Master Fund Ltd., and by contract exercises voting and investment power over those shares; Mr. Boyd, as managing member, is likewise attributed shared voting and dispositive power. The filing indicates the holdings are reported as being held in the ordinary course of business and not for the purpose of changing control.
Cosmos Health Inc. entered into a Securities Purchase Agreement and, at the initial closing, issued a 9% original-issue-discount senior secured convertible promissory note with an aggregate original principal amount of $8,000,000. The Initial Note matures on August 7, 2027 and bears interest at 9% per annum, computed on a 360-day year and payable in arrears monthly on the first calendar day of each month beginning September 1, 2025. Interest may be paid in shares of common stock, in cash, or a combination, subject to the Note's Equity Conditions.
The Initial Note is convertible into shares of common stock; the Conversion Shares are determined by dividing the Conversion Amount by the lower of the Conversion Price of $1.05 and the Market Price. The holder faces a Beneficial Ownership Limitation of 4.99% of outstanding common stock immediately after conversion (adjustable up to 9.99% after notice, effective 61 days after notice). The Note ranks senior to other indebtedness except permitted indebtedness, contains customary events of default that raise the interest rate to 16% upon default, and was sold in a private offering under Section 4(a)(2) of the Securities Act. The form of the Note is filed as Exhibit 4.1.